OEGSTGEEST, The Netherlands, November 30, 2021 / B3C News Wire / – Toxys BV is a biotech company based in Leiden, the Netherlands, which provides innovative and high fidelity products in vitro toxicity screening solutions to identify carcinogenic and other hazardous properties of compounds for the pharmaceutical, chemical, cosmetic and food industry. Today, Toxys announces the creation of its Scientific Advisory Board to help guide the development of innovative animal-free tests to ensure the safety of new drugs and other products for humans. With the Scientific Advisory Board, Toxys will further accelerate its business growth to become an industry leader in chemical safety assessment.
Legend: From left to right: Bob van de Water, Clive Roper, Peter Boogaard, Giel Hendriks, Torben Ãsterlund.
For high resolution, please click on the picture
âI am extremely happy and proud to be able to announce the nominations of the members of our Scientific Advisory Board. They are all internationally renowned scientific experts in the fields of chemical safety assessment and alternatives to animal testing. The expertise of these new members of the Scientific Council will further strengthen our R&D activities and is an important step in further enabling Toxys to grow. said Torben Ãsterlund, CSO of Toxys BV and President of SAB.
The members of the new Toxys Board of Directors are:
Bob van de Water obtained his doctorate in 1995 from the University of Leiden. He is Professor of Drug Safety Sciences at the Leiden University Center for Drug Research at Leiden University and Head of the Division of Drug Discovery and Safety. He has been working on the molecular mechanisms of toxicity for over 30 years. This work has led to the development of fluorescent protein reporter platforms to quantify cellular responses to stress in relation to exposure to chemicals and drugs and to qualify the responsibility for adverse responses. He is currently the coordinator of the EU-ToxRisk project which has worked on integrated testing strategies for read-across, applying new approach methodologies. He is also coordinating the recently funded RISK-HUNT3R project which will focus on next generation risk testing strategies.
Clive roper holds a doctorate in in vitro skin toxicology from the University of Newcastle. From 1996 to 2021 he worked for Charles River, becoming director, in vitro toxicology responsible for skin absorption, regulatory in vitro toxicology, geneticox, safety pharmacology and in vitro respiratory toxicology. Clive is the author and co-author of numerous posters and abstracts and is a regular peer reviewer. He has developed models leading to direct replacement of animals in skin absorption, skin toxicology and inhalation toxicology. He is a member of the North American 3Rs Collaborative and sits on the Microphysiology Subgroup (MPS) and a member of the UK NC3Rs Board of Directors. In 2021, Clive established his consulting firm, Roper Toxicology Consulting Limited, helping to develop new methodologies of approaching SMEs and supporting regulatory acceptance of products in the market.
Peter Boogaard holds degrees in pharmacy and chemistry and a doctorate in toxicology from the University of Leiden. After joining Shell in 1990, he held a number of positions, including Head of Shell Biomedical Services and Global Discipline Manager and Toxicology Officer, with global responsibility for product and drug health risk assessments. process. In addition, he is Professor of Environmental Health and Human Biomonitoring in the Division of Toxicology at Wageningen University. He has been chairman of the toxicology group of CONCAWE, member of the scientific council of ECETOC and other tripartite committees on chemical risk assessment such as ILSI-HESI and the long-term research program of CEFIC . He has served on several committees of the Netherlands Health Council, including the Dutch Expert Committee on Professional Standards and the Carcinogens Evaluation Committee. In addition, he is scientific advisor on risk assessment for the European Commission and has served on the scientific committee on occupational exposure limits. He is (co-) author of more than 300 scientific publications and reports, in the fields of occupational toxicology, NAMS, human biomonitoring, dermal exposure, reproductive toxicity, nephrotoxicity and risk assessment (of cancer).
Toxys is a Dutch biotechnology company that offers a wide range of innovative products in vitro toxicological solutions. Toxys was founded in 2014 as a spin-off of Leiden University Medical Center and has its state-of-the-art laboratory facilities located in the Leiden Bio Science Park. Toxys is an expert in toxicological research with the mission of improving animal-free safety testing by creating in vitro chemical safety testing to meet the need for safer drugs, chemicals and cosmetics. Toxys has developed the unique ToxTrackerÂ®, ReproTrackerÂ® and ToxProfiler â¢ tests. ToxTracker is a high throughput stem cell based assay suite that enables reliable identification of genotoxic carcinogens. ReproTracker is an animal-free test to identify compounds that are toxic to human embryonic development. ToxProfiler is a human cell test for mechanistic toxicity testing.
Toxys currently works with seven of the world’s ten largest pharmaceutical companies and several large multinational chemical, cosmetic and food companies and is highly regarded for its scientific expertise, high quality results and responsiveness.
+31 71 3322474
Keywords: Humans; Toxicity tests; Chemical safety; Alternatives to animal testing; Drug-related side effects and adverse reactions; Animals; Carcinogens; Carcinogenesis; teratogens; DNA damage; Stem cells; Biological dosage; Cell differentiation; Safety of consumer products; Mutagenicity tests; pharmaceutical preparations; Biotechnology; Industry; Food industry; Beauty products; Netherlands
Posted by B3C News Wire